Recent Articles

• 
  Biotech

  Moderna Cancer Vaccine Succeeds; Korean Tech Eyes 2027 Trial

  Cancer vaccine image. As the patient-specific mRNA cancer vaccine jointly developed by Moderna and Merck has produced positive results in a Phase 3 clinical trial for high-risk melanoma patients, interest in the development of personalized cancer vaccines is increasing. Getty Images Bank The patient

  2026.08.20
• 
  Celltrion

  Celltrion Tops Asia for Remsima, Cancer Drugs, Expands Pipeline

  Panoramic view of a Celltrion plant. Provided by Celltrion. Celltrion stated on the 19th that its key product lines, including autoimmune disease treatments and anticancer drugs, continue to maintain high market shares in major Asian markets. In Malaysia, Singapore, and Thailand, the company is oper

  2026.08.19
• 
  Biopharma

  SK Biopharm, Xcopri Generic Settle Patent Dispute

  SK Biopharmaceuticals announced on the 19th that it had reached a settlement with Indian generic company MSN Laboratories in a patent lawsuit related to “XCOPRI,” the U.S. product of its epilepsy drug cenobamate. As a result, the litigation between the two companies pending before the U.S. District

  2026.08.19
• 
  Biopharma

  Aims Tackles Antimicrobial R&D Bottlenecks, Links Labs

  AIMS Bioscience (AIMS), a new drug development strategy consulting company of the Il-Dong Pharmaceutical Group, announced on the 18th that it has been selected as the implementing agency for the project titled “Planning of an Operations Model for a Distributed Infrastructure-Linked Technical Support

  2026.08.18
• 
  Global Business

  CKD Bio Seeks China Botox Approval, Eyes 2027 Launch

  Chungjeongno headquarters of Chong Kun Dang. Provided by Chong Kun Dang Chong Kun Dang Bio announced on the 18th that it has submitted a Biologics License Application (BLA) for its independently developed botulinum toxin product “CU-20101” to China’s National Medical Products Administration (NMPA).T

  2026.08.18
• 
  AI Healthcare

  Bidraft’s AI Drug Discovery Challenge Tops 2,000 Entries

  Provided by VIDRAFT Artificial intelligence (AI)-based scientific research company VIDRAFT has launched an open new drug candidate discovery project, the “Open Discovery Challenge,” which has drawn attention by collecting more than 2,000 participation data entries within three days of being released

  2026.08.18
• 
  Diagnostics / Monitoring

  Exercise-linked protein may serve as early dementia alarm

  Getty Images Bank Protein released from muscles during exercise may serve as an “early warning” indicator of dementia risk, according to a domestic research finding. Observers say this opens the way to identify the risk of Alzheimer’s disease before symptoms appear, using only a simple blood test. I

  2026.08.18
• 
  Pharmaceutical R&D

  Korean Team Triples mRNA Efficacy Using Viral Mechanism

  The efficacy of messenger ribonucleic acid (mRNA)-based therapeutics, which are genetic information carriers, has been enhanced by a newly developed technology. The method increases protein production by allowing mRNA to remain longer inside cells, applying the principle by which viruses protect the

  2026.08.14
• 
  Diagnostics / Monitoring

  SK Bioscience wins approval for triple virus test kit

  InstaQ product (left) and POCT reader InstaRead M (right). Provided by SG Biosciences SG Biosciences has received approval from the Ministry of Food and Drug Safety for a respiratory virus multiplex diagnostic kit that can test for coronavirus disease (COVID-19), influenza A and B, and respiratory s

  2026.08.13
• 
  Pharmaceutical R&D

  TH Pharm Uses AI Redesign to Expand Metabolic Treatments

  Metabolic disease drug development specialist THPharm is pursuing a strategy to expand treatment scope (indications) through bio-AI-based “reverse engineering” in collaboration with global AI drug discovery company Insilico Medicine.“Reverse engineering” is a technique that, unlike the conventional

  2026.08.13